← Eichor
Study identifier: NCT06353906 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer

Condition: Urologic Neoplasms · Urogenital Neoplasms · Male Urogenital Diseases  ·  Sponsor: The Netherlands Cancer Institute

PhasePhase 2
Planned participants27
Who can joinMale, 18 Years to no upper limit
Healthy volunteersNo

About this study

This is a single-armed, single-centre, non-blinded phase II trial to assess efficacy of induction chemo-immunotherapy for resectable node-positive squamous cell carcinoma of the penis

This description comes directly from the study's public registry record.

Talk to the study team

Michiel S. van der Heijden, PhD  ·  +31205129111  ·  ms.vd.heijden@nki.nl

Jan-Jaap J. Mellema, MD  ·  +31205129111  ·  j.mellema@nki.nl

Always discuss trial participation with your own doctor first.

Locations (2)

UZ LeuvenLeuven, BelgiumRecruiting
NKI-AVLAmsterdam, North Holland, NetherlandsRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06353906